Karyopharm announces expansion of royalty agreement with healthcare royalty for up to $100 million

Newton, mass., june 24, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by healthcare royalty management, llc (hcr) for up to $100 million in new financing to support the ongoing development and commercialization of xpovio® (selinexor), the company's first-in-class, oral selective inhibitor of nuclear export (sine) compound, and for the clinical development of karyopharm's other programs, including eltanexor.
KPTI Ratings Summary
KPTI Quant Ranking